Repligen Corp (RGEN) · Sep 15, 2026 · Exec change

Repligen loses 20-year director Dawes as CEO transition gives way to renewal

Director retirement — Effective September 30, 2026

Karen Dawes will leave Repligen’s board after more than 20 years. The change is notable for governance continuity, but no operating shift is disclosed.

Repligen is a bioprocessing-technology company rebuilding growth as biologics demand normalizes, with 2025 revenue growth and a completed CEO handoff to Olivier Loeillot. This is a governance transition, not an operating event. Karen Dawes is retiring from the board effective September 30 after more than 20 years of service. 〔0〕 The filing gives no replacement, committee reshuffle, strategic change, or financial impact, so it does not alter the company’s commercial or execution story. The main signal is that the leadership reset is continuing beyond the CEO role. Dawes explicitly links her timing to the completed CEO transition, saying she believes “now is the right time” to retire. 〔1〕 That makes this look more like planned board renewal than a loss of operating leadership, although her long tenure means some institutional knowledge leaves with her. Bottom line: This closes another chapter of Repligen’s leadership transition, but without a named successor or business consequence, it is largely a governance housekeeping event rather than a change to the investment story.

What to watch next

Dawes retirement effective September 30, 2026

Original filing on SEC EDGAR

More Repligen Corp news

Repligen loses 20-year director Dawes as CEO transition gives way to renewal | RGEN Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.